Press Releases

Sign Up For Updates
Date Description View
11/06/19

Test

11/06/19

Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights

09/03/19

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson's Disease and Launch of its Engage Parkinson's website

08/05/19

Denali Therapeutics Announces that its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study

06/11/19

Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs

05/07/19

Denali Therapeutics Reports First Quarter 2019 Financial Results

03/12/19

Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights

02/15/19

Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for Alzheimer’s Disease

01/08/19

Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for ALS

12/10/18

Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL201 for Parkinson's Disease


Sign up for email alerts

Stay in the loop with updates on the latest Denali news delivered right to your inbox

Required fields denoted by an asterisk (*).

Investor & Media Relations